MicoleErmine.bsky.social

I know, there has already been deaths in the camps but no “final Solution” level deaths yet

Saw this and grimaced

I was in that program in the 80’s and I have all those problems…. They didn’t figure out I had ADHD until my 30’s so there’s that.

I got to say hello to @kencougr.bsky.social and @micoleermine.bsky.social, huzzah. It's been a really long time since I've seen them in person, so I was very glad I got the chance. 😊

All the taco-esk meat dishes!

An Iron Maiden inspired band shirt based on the "The Trooper" album cover. Maid Marian (Disney's Robin Hood) brandishing a sword and carrying St. George's Cross across a battlefield under the title "Iron Maid Marian"

Today's low-key furry shirt.

that checkpoint inhibitor drugs such as anti-PD-1 therapy -already used in hospitals- work best when they expand these stem-like and metabolically fit T-cells. In contrast, people whose immune reactions were regulated by exhausted cells fared badly. When checkpoint therapy was administered with

Figure 1. Tailoring NP engineering to augment cytokine synergy and antigen presentation

“stem-like" T-cells. These cells, characterized by genes TCF1 and LEF1, could self-renew and differentiate into new waves of fighters. If these cells were removed from mouse models, immune attacks collapsed; if they were grown, tumors disappeared and survival increased. Researchers also discovered

chemical messenger that recruits other immune defenses. The studies showed that metabolic flexibility, not target recognition, foretells how long the immune cells will keep fighting. Among the populations of tumor-infiltrating T-cells that were so diverse, one stood out as extraordinary: a subset of

glycolysis, they switched to oxidative phosphorylation and fatty acid metabolism- an energy strategy that enables them to endure the long term. When researchers boosted these channels of energy in mice, the T-cells killed tumor cells better and produced higher levels of interferon-γ, an immune

single-cell resolution, the researchers identified a minor subset of tumor-cytotoxic cells. These cells continue to function even in oxygen-starved, nutrient-poor environments in which other immune cells do not. These hardy T-cells employed a second fuel source. Instead of combusting glucose through

patients, the treatments fail because immune cells become exhausted. Tumors naturally adapt to disable or tire out the same cells meant to kill them. Researchers mapped how CD8⁺ T cells-the body's own killers-are capable of surviving and fighting within solid tumors. By examining the cells at

place. Taken together, the breakthroughs promise a day when the body's own immune system can prevent and fight cancer with greater accuracy and endurance. Cancer immunotherapy transformed the treatment of most cancers by unleashing the potential of the immune system to kill tumors. Yet, in most

In a breakthrough that could potentially rewrite the prevention and treatment of cancer, researchers have discovered how certain immune cells can break through tumors’ defenses. They have also developed a new nanoscale vaccine that shows promise in preventing cancers from occurring in the first

Melanoma, pancreatic cancer, and triple-negative breast cancer (TNBC) are each serious clinical challenges due to how common or aggressive they are and how poorly they often respond to treatment. Which is why researchers are determined to develop an effective treatment for all of them.

HIGHLIGHTS • Lipid NPs carrying STING and TLR4 agonists promote synergistic type I interferons • NPs drain efficiently to lymph nodes and increase polyfunctional T and B cells • NPs improve tumor-free outcomes with memory against multiple aggressive tumor models SUMMARY We report on the utility of a "super-adjuvant" nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness not only the effective adjuvanticity of whole-pathogen vaccines, but also the safety of subunit vaccines. Our lipid-based NP platform co-encapsulates agonists of the stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) pathways to promote synergistic production of type I interferons and other proinflammatory cytokines in innate antigen-presenting dendritic cells and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs administered with antigenic peptides or tumor cell lysate promote increased antigen processing and presentation, drain efficiently to nearby lymph nodes, increase polyfunctional tumor-specific T and B cells, and improve tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells.

Graphical Abstract The vaccine combines two immune-stimulating molecules (adjuvants) in a tiny lipid nanoparticle that enhances both innate and adaptive immune responses. The innate immune system acts as the body’s first line of defense, responding quickly and non-specifically to invaders using cells that release inflammatory signals. The adaptive immune system takes longer to activate but provides a targeted, long-lasting response, training T-cells and B- cells to recognize and remember specific threats. Together, they form a coordinated defense: the innate system alerts and activates the adaptive system, which then delivers precise and durable immunity.

Researchers envision their vaccine being used as both a treatment and a preventive, and as an approach to treating multiple cancer types. NOTE: This is PRECLINICAL.
• www.umass.edu/news/article...

The study has been published in Cell. YES, it is PEER-REVIEWED.
• www.cell.com/cell-reports...

🧪🧵⬇️

GOOD NEWS! Researchers have developed a cancer vaccine that has shown STUNNING results, PREVENTING up to 88% of MULTIPLE aggressive cancers by harnessing dual-pathway nanoparticles that train the immune system to recognize and destroy tumor cells. In some cases, it COMPLETELY prevented metastasis.

Hit the trail! 🪧

[ #art #designs ]

Snow day! I think this was my most widely-shared piece on the dead bird site. ❄

#art #animals

Butlerian Jihad incoming.

It's a tradition in Scotland for the road gritters too

They named the snowplows 🥹

Most of Deals art is still packed in our house— Ken has it.

1989 by Deal Whitley.

1988 by Ken Sample

Time for another #OldArtMonday

Here is "Topher, the world's cutest otter" -- but giant.

The pencils are from 1988 by @kencougr.bsky.social

The inked image is from 1989 by Topher's creator Deal Whitley.

Ken would have fun drawing people's characters giant with the byline "slightly altered."

Get more from Terrie Smith on Patreon Patreon is empowering a new generation of creators. Support and engage with artists and creators as they live out their passions!

It looks like Terrie Smith will need heart surgery for a leaky valve. She could use your support more than ever.

www.furaffinity.net/journal/1125...

She's currently posting colorized Havoc Inc. pages on her Patreon, consider subscribing or sending a donation.

www.patreon.com/TerrieSmith

This dimwitted coward is taking on *Mark Kelly*? Space station commander combat tested Navy aviator Mark Kelly?

🍿🍿🍿🍿🍿🍿🍿

A comic of two foxes, one of whom is blue, the other is green. In this one, Blue is laying on the floor, suffering, as Green peers at him cautiously. Green: How's your headache? Can I help in any way? Blue: Not really. I just have to suffer through it. Having produced an antique-style velvet-cushioned fainting couch, apparently out of nowhere, Green places Blue upon it. Blue rests on his back, still exactly just as miserable as before. Green: Would you feel better suffering on a nice fainting couch? Blue: It's not worse. Closing his eyes, Green cuddles up to Blue, loosely wrapping around him. Green: What if I lay down too, draped dramatically over you, lamenting your grievous fate? Blue: You don't have to do all that. Green: But I want to.

A comic of two foxes, one of whom is blue, the other is green. In this one, Blue jumps in shock as Green floats idly by him. Green: I don't feel like doing today. Blue turns his head to follow where Green is going as Green floats further away. Blue: Doing what today? Green: Just the whole day. Any of it. As Green drifts out of sight, Blue raises his eyebrow, puzzled, watching where Green drifted off to. Blue: Also why are you floating? Green, out of frame: I got excommuned by gravity. Blue stares after Green, now in blank bafflement. Blue: ...What?